Vor Biopharma Inc (VOR)
1.43
+0.08
(+5.93%)
USD |
NASDAQ |
Jun 03, 16:00
1.435
0.00 (0.00%)
Pre-Market: 20:00
Vor Biopharma Cash from Investing (TTM): 108.48M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 108.48M |
December 31, 2023 | 71.01M |
September 30, 2023 | -36.36M |
June 30, 2023 | -64.20M |
March 31, 2023 | -80.54M |
December 31, 2022 | -94.09M |
September 30, 2022 | -3.008M |
Date | Value |
---|---|
June 30, 2022 | -24.20M |
March 31, 2022 | -97.54M |
December 31, 2021 | -91.65M |
September 30, 2021 | -87.18M |
June 30, 2021 | -80.28M |
March 31, 2021 | -4.787M |
December 31, 2020 | -4.161M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-97.54M
Minimum
Mar 2022
108.48M
Maximum
Mar 2024
-34.89M
Average
-50.28M
Median
Cash from Investing (TTM) Benchmarks
Masimo Corp | -89.00M |
AnaptysBio Inc | 127.97M |
Apellis Pharmaceuticals Inc | -0.708M |
NovaBay Pharmaceuticals Inc | 1.062M |
Palatin Technologies Inc | 9.41M |